Dexcom (DXCM) Asset Writedowns and Impairment (2014 - 2017)

Dexcom (DXCM) has 4 years of Asset Writedowns and Impairment data on file, last reported at $4.7 million in Q4 2017.

• On a quarterly basis, Asset Writedowns and Impairment rose 193.75% year-over-year to $4.7 million in Q4 2017; TTM through Dec 2017 was $7.9 million, a 259.09% increase from a year earlier, with the FY2017 full-year figure at $7.9 million, up 259.09% from the prior year.
• Asset Writedowns and Impairment for Q4 2017 stood at $4.7 million, up from -$2.9 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for DXCM reached as high as $5.7 million in Q2 2017 and fell as low as -$2.9 million in Q3 2017.
• Historically, Asset Writedowns and Impairment has averaged $1.2 million across 4 years, with a median of $400000.0 in 2017.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 300.0% in 2017 and fell as far as 680.0% in 2017.
• Year by year, Asset Writedowns and Impairment stood at $100000.0 in 2014, then jumped by 100.0% to $200000.0 in 2015, then soared by 700.0% to $1.6 million in 2016, then soared by 193.75% to $4.7 million in 2017.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $4.7 million in Q4 2017, -$2.9 million in Q3 2017, and $5.7 million in Q2 2017.